Business Context and Reporting Period
Company: Pluristem Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date: December 20, 2016
Context: The registrant announced the signing of a binding term sheet with Sosei Corporate Venture Capital Ltd. ("Sosei CVC") to establish a new Japanese corporation ("NewCo"). This entity will focus on the clinical development and commercialization of Pluristem's PLX-PAD cell therapy product for Critical Limb Ischemia (CLI) in Japan.
Key Financial Metrics and Transaction Details
This filing reports a strategic transaction rather than periodic financial performance. Consequently, standard metrics such as revenue, profit, cash flow, margins, and debt are not provided in this document.
- Investment Amount: Approximately $11 million (equivalent to approximately ¥1.3 billion).
- Investors: Sosei RMF1 (Sosei CVC's investment fund) and additional Japanese investors.
- Equity Structure: Pluristem will own 35% of NewCo; investors will own 65%.
- Consideration: Pluristem contributes a perpetual license to commercialize PLX-PAD for CLI in Japan.
- Intellectual Property: All proprietary rights related to PLX-PAD remain exclusively owned by Pluristem.
Material Changes and Outlook
Material Change: The entry into a binding term sheet represents a material definitive agreement aimed at expanding the company's commercial footprint in Japan without diluting ownership of the core IP.
Guidance and Timeline: The parties plan to enter into a definitive agreement no later than March 31, 2017.
Risks and Contingencies:
- The transaction is subject to the negotiation and execution of definitive documentation, which may not occur by the expected date or at all.
- Completion of the transaction is contingent upon meeting specific closing conditions.
- Forward-looking statements regarding the establishment of NewCo and investment amounts are subject to uncertainties that could cause actual results to differ materially.
Key Facts for Investor Verification
- Verify the execution of the definitive agreement by the March 31, 2017 deadline.
- Confirm the final capitalization structure of NewCo and the exact amount of capital raised.
- Review the specific terms of the perpetual license granted to NewCo regarding PLX-PAD in Japan.
- Monitor the progress of the clinical development and commercialization plans for PLX-PAD in the Japanese market.